Investors who purchased or otherwise acquired Aardvark Therapeutics, Inc. securities between February 10, 2025 and May 14, 2026 have until October 13, 2026 to ask the court for appointment as lead plaintiff in a putative securities class action. The lawsuit alleges that Aardvark and its executives made materially false or misleading statements about ARD-101’s safety and clinical, regulatory and commercial prospects. The case follows two sharp stock-price declines after the company disclosed a voluntary pause of its Phase 3 HERO trial and later said the U.S. Food and Drug Administration (FDA) had placed a full clinical hold on the drug’s investigational new drug application (IND).